Ghislaine Maxwell's transfer to a minimum-security prison in Texas raises questions about preferential treatment and a potential cover-up in the Epstein case.
Regeneron beats Q2 earnings estimates on strong Dupixent sales, despite challenges with Eylea and regulatory delays.
Ghislaine Maxwell's transfer to a minimum-security prison in Texas raises questions about preferential treatment and a potential cover-up in the Epstein case.
Regeneron beats Q2 earnings estimates on strong Dupixent sales, despite challenges with Eylea and regulatory delays.